Olivia Coughlin

Learn More
BACKGROUND SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous β-lactam antibiotics like cephalosporins. SYN-004 is intended to degrade residual antibiotics excreted into the intestine as a result of hepatobiliary excretion and to prevent the disruption of the gut microbiome by these excess(More)
SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics, including most penicillins and cephalosporins. Ribaxamase's anticipated mechanism of action is to degrade excess β-lactam antibiotic that is excreted into the small intestine. This enzymatic inactivation of excreted antibiotic is(More)
Determinants of Intestinal Permeability in Healthy First Degree Relatives of Crohn’s Disease Patients, W. Turpin, D. Kevans, K. Shestopaloff, M. Smith, D. Guttman, M. Silverberg, W. Xu, A. Paterson, and K. Croitoru University of Toronto, Toronto, ON, Canada Mount Sinai Hospital, Toronto, ON, Canada Dalla Lana School of Public Health, Toronto, ON, Canada(More)
There is growing evidence that methane production, predominantly by Methanobrevibacter smithii, in the intestines is a cause of constipation, pain, and bloating in irritable bowel syndrome with constipation (IBS-C). M smithii resides primarily in the large intestine but can also colonize the small intestine. In vitro studies found that the prodrug lactone(More)
Background. Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to prevent new onset CDI. SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered with IV β-lactam antibiotics and remain localized in the intestine to degrade antibiotics excreted into the intestine. This is expected to(More)
  • 1